ClinicalTrials.gov
ClinicalTrials.gov Menu

Ergospirometric Values and WBV in Elderly (EVAWIE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01681719
Recruitment Status : Completed
First Posted : September 10, 2012
Last Update Posted : September 10, 2012
Sponsor:
Information provided by (Responsible Party):
Maíra F Pessoa, Universidade Federal de Pernambuco

Brief Summary:
this study aims evaluate the ergospirometric values after 03 months of training with WBV in elderly health people. The hypothesis is increases of ergospirometric values.

Condition or disease Intervention/treatment Phase
Aging Device: WBV and Resistance Device: resistance & sham WBV Device: WBV & resistance sham Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Whole Body Vibration as Alternative for Improve the Ergospirometric Values in Elderly: a Randomized Clinical Trial
Study Start Date : January 2011
Actual Primary Completion Date : December 2011

Arm Intervention/treatment
Experimental: WBV and resistance
used both interventions
Device: WBV and Resistance

use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.

For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.

For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.

Experimental: WBV & resistance sham
used the vibrating platform and sham for resistance training
Device: WBV & resistance sham

used really the WBV, but sham for resistance training

For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.

For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min.

Experimental: Resistance & sham WBV
used resistance exercises and sham for vibrating platform
Device: resistance & sham WBV

used only resistance

For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.

For WBV: used MY3 platform (Power Plate®, MY3, UK)off.




Primary Outcome Measures :
  1. maximal O2 consumption [ Time Frame: started and finished the protocol after 03 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • aged 60-74 years,
  • Sedentary or Moderate A in accord with IPAQ short form (International Physical Activity Questionnaire) and those without disease.
  • furthermore, the subjects should reach the ventilatory threshold 1, considered after meeting two of the following events:
  • respiratory quotient (R) increases (R ≥1,1);
  • loss of linearity between the pulmonary ventilation curve (VE) and oxygen consumption (VO2), plateau of VO2 or plateau of heart rate (HR) and increases of end-tidal PO2 (Pet O2)

Exclusion Criteria:

  • Were excluded subjects with changes in Mini-mental state examination (MMSE) scores by age and educational level where the minimum score represents: illiterate 13 points, less than 8 study years is 18 points, 8 or more study years is 26 points 11.
  • Were also excluded current smokers or previous, subjects with thrombosis, labyrinthitis, diabetes, hemodynamic instabilities, obesity, osteoporosis, neuromuscular diseases, pulmonary or cardiac diseases, changes in resting electrocardiogram or in exercise, ingestion of drugs to metabolism bone / muscle / heart chronotropism or with difficulties in adapting protocols

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01681719


Locations
Brazil
UFPE
Recife, Pernambuco, Brazil, 50740-560
Sponsors and Collaborators
Maíra F Pessoa

Responsible Party: Maíra F Pessoa, Principal Investigator, Universidade Federal de Pernambuco
ClinicalTrials.gov Identifier: NCT01681719     History of Changes
Other Study ID Numbers: ERGOFORCE1
First Posted: September 10, 2012    Key Record Dates
Last Update Posted: September 10, 2012
Last Verified: September 2012

Keywords provided by Maíra F Pessoa, Universidade Federal de Pernambuco:
VO2
VCO2
VE/VO2
heart rate